Company facts
- Headquarters
- Millbrae, California
- Most recent report
- 8-K, filed Aug 14, 2026
- Incorporated
- Delaware
- Filings on record
- 62 filings
- On EDGAR
- CIK 1861123
- Fiscal year ends
- December
- Filer status
- Emerging growth company
Financials 3
News 8
Prospectuses and Registrations 4
Ownership 8 of 35
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 6, 2026
- 3 Insider reported their initial holding Jun 15, 2026
- SCHEDULE 13G Large holder reported a passive stake May 15, 2026
- SCHEDULE 13G Large holder reported a passive stake May 13, 2026
- SCHEDULE 13G Large holder reported a passive stake May 6, 2026
- SCHEDULE 13G Large holder reported a passive stake Apr 29, 2026
- 4 Insider reported a trade Mar 4, 2026
- 4 Insider reported a trade Mar 4, 2026
Other 8 of 12
- S-1MEF Feb 4, 2026
- CERT Exchange certified a listing Feb 4, 2026
- EFFECT Notice that a registration became effective Jan 30, 2026
- 8-A12B Registration of a security for exchange listing Jan 28, 2026
- DRS/A Draft registration statement, submitted confidentially, amended Dec 12, 2025
- DRS/A Draft registration statement, submitted confidentially, amended Sep 26, 2025
- DRS/A Draft registration statement, submitted confidentially, amended Jul 1, 2025
- DRS Draft registration statement, submitted confidentially May 9, 2025
Everything here comes from Eikon Therapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.